Novo Nordisk completes second and final phase 3a trial with liraglutide as adjunct therapy to insulin for people with type 1 diabetes (NN9211) Bagsværd, Denmark, 24 August 2015 - Novo Nordisk today ...
Please provide your email address to receive an email when new articles are posted on . To assess treatment preferences, Pettus and colleagues sent a survey and received responses from 1,313 adults ...
Objective To compare the effectiveness of adjunct treatments combined with exercise to exercise alone in people with patellofemoral pain (PFP) and explore the quality of intervention descriptions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback